The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Cognitive Deficits and Mood Disorders in Parkinson's Disease, 2008Validation of the Dopamine-depleted CHT Hemizygous Pre-Clinical Model as an Animal Model of Parkinson's Disease with Dementia
Objective/Rationale:
Parkinson’s disease is traditionally thought of as a motor disorder. However, in addition to problems with movements, patients frequently develop cognitive problems leading to... -
Cognitive Deficits and Mood Disorders in Parkinson's Disease, 2008Validating the Montreal Cognitive Assessment for the Diagnosis of Mild Cognitive Impairment in Parkinson's Disease
Objective/Rationale:
Dementia affects up to 80 percent of Parkinson’s disease patients, and the prevalence of other dementias including Alzheimer’s disease is high in this age group. A need exists for... -
Rapid Response Innovation Awards, 2008Screen for Drugs to Reduce ER Stress
Objective/Rationale:
Humans are exposed to agents and conditions that cause stress to dopaminergic neurons. Neurons can survive stress by modulating the biosynthesis and degradation of proteins within... -
Rapid Response Innovation Awards, 2008DNA Methylation as an Epigenetic Mechanism in the Etiopathogenesis of Parkinson's Disease
Objective/Rationale:
The objective of this research is to determine whether epigenetic factors play a role in the development of sporadic Parkinson’s disease. Epigenetic factors are chemical... -
Rapid Response Innovation Awards, 2008Generating Patient-Specific Induced Pluripotent Stem Cells to Study Parkinson's Disease
Objective/Rationale:
One of the major hurdles for Parkinson’s research is the lack of live dopamine neurons from patients for long-term studies and drug screens. This project will use the newly... -
Rapid Response Innovation Awards, 2008Posiphen as a Well-tolerated Alpha-synuclein Inhibitor and a Potential 5'UTR Directed Drug Treatment of Parkinson's Disease
Objective/Rationale:
An inter-relationship exists between the Parkinson’s disease-related protein alpha-synuclein and the Alzheimer’s Aß-amyloid plaque protein. Phenserine reached clinical assessment...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.